Suppr超能文献

多维前列腺特异性抗原检测的医疗保健获取障碍:2006 年至 2020 年美国全国面板研究。

Multidimensional Healthcare Access Barriers to Prostate-Specific Antigen Testing: A Nation-Wide Panel Study in the United States From 2006 to 2020.

机构信息

Section of Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.

Department of Population Health Sciences, Weill Cornell Medical Center, New York, New York, USA.

出版信息

Cancer Med. 2024 Nov;13(21):e70358. doi: 10.1002/cam4.70358.

Abstract

BACKGROUND

Rising metastatic prostate cancer incidence has renewed debate regarding benefits of prostate-specific antigen (PSA) screening. Identifying barriers to accessing screening for individuals at high risk of lethal prostate cancer may slow this rise. We examined associations of access barriers with receipt of PSA testing, stratified by sociodemographic factors.

METHODS

We pooled data from male respondents to Behavior Risk Factor Surveillance Systems (BRFSS) surveys from 2006 to 2020. Questions related to affordability (insurance, cost of visits) and accommodation (regular primary care provider (PCP), physician recommending a PSA test) were considered as individual-level barriers. For availability, we linked provider density from the 2012 Area Health Resource File and estimated driving times to closest health facility within Micropolitan and Metropolitan Statistical Area (MMSA) using Google Earth Engine. These measures were used to compute a spatial accessibility index. We fit survey-weighted, covariate-adjusted logistic regression models to estimate associations of barriers with receipt of PSA within the past 2 years and examined effect modification by sociodemographic factors.

RESULTS

There were 185,643 participants, of whom 73% were White, 11% were Black, 4% were Asian, and 11% were Hispanic. Physician recommendation was the strongest predictor of having a PSA test (aOR: 14.5, 95% CI: 13.6, 15.6). Not having a regular PCP (aOR: 0.29, 95% CI: 0.27, 0.31), insurance (aOR: 0.64, 95% CI: 0.58, 0.71), and prohibitive cost of care (aOR: 0.82, 95% CI: 0.75, 0.90) were associated with lower PSA testing. Access barriers were stronger predictors of PSA testing for Asian and White participants compared to other groups (P < 0.004 for insurance and regular PCP) and for those with college education compared to those without (P < 0.05 for insurance, perceived unaffordability).

DISCUSSION

Physician recommendation was the strongest predictor of receipt of PSA testing, regardless of sociodemographic grouping. Future studies should consider access barriers jointly and across sociodemographic strata.

摘要

背景

不断上升的转移性前列腺癌发病率再次引发了关于前列腺特异性抗原(PSA)筛查益处的争论。识别高危致命性前列腺癌个体的筛查障碍可能会减缓这种上升趋势。我们通过社会人口统计学因素分层,研究了获得障碍与 PSA 检测接受率之间的关联。

方法

我们从 2006 年至 2020 年的男性行为风险因素监测系统(BRFSS)调查中汇总了数据。可负担性(保险、就诊费用)和可及性(定期初级保健提供者(PCP)、医生推荐 PSA 检测)相关问题被视为个体层面的障碍。对于可及性,我们从 2012 年的区域卫生资源档案中链接了提供者密度,并使用谷歌地球引擎估计了到 Micropolitan 和大都市统计区(MMSA)内最近的卫生设施的驾驶时间。这些措施用于计算空间可及性指数。我们拟合了调查加权、协变量调整的逻辑回归模型,以估计过去 2 年内障碍与 PSA 检测接受率之间的关联,并检查了社会人口统计学因素的效应修饰作用。

结果

共有 185643 名参与者,其中 73%为白人,11%为黑人,4%为亚洲人,11%为西班牙裔。医生的推荐是进行 PSA 检测的最强预测因素(优势比:14.5,95%置信区间:13.6,15.6)。没有定期的 PCP(优势比:0.29,95%置信区间:0.27,0.31)、保险(优势比:0.64,95%置信区间:0.58,0.71)和医疗费用过高(优势比:0.82,95%置信区间:0.75,0.90)与较低的 PSA 检测率相关。与其他群体相比(保险和定期 PCP 方面,P < 0.004;与没有大学学历的人相比,P < 0.05,保险、感知不可负担性方面),获得障碍对于亚裔和白人参与者来说是 PSA 检测的更强预测因素。

讨论

无论社会人口统计学分组如何,医生的推荐都是 PSA 检测接受率的最强预测因素。未来的研究应该联合考虑并跨越社会人口统计学阶层来考虑获得障碍。

相似文献

2
Screening for prostate cancer.前列腺癌筛查
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3.
8
Small Area Estimation of PSA Testing in US States and Counties.美国各州及各县前列腺特异性抗原检测的小区域估计
Cancer Epidemiol Biomarkers Prev. 2025 Jan 9;34(1):197-204. doi: 10.1158/1055-9965.EPI-24-1086.
10
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.

本文引用的文献

3
Understanding inequities in precision oncology diagnostics.理解精准肿瘤诊断中的不公平现象。
Nat Cancer. 2023 Jun;4(6):787-794. doi: 10.1038/s43018-023-00568-1. Epub 2023 May 29.
6
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
8
Trends in Incidence of Metastatic Prostate Cancer in the US.美国转移性前列腺癌发病率的趋势。
JAMA Netw Open. 2022 Mar 1;5(3):e222246. doi: 10.1001/jamanetworkopen.2022.2246.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验